Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Dec 9, 2010

Premium

Title: Methods and Means for Producing Efficient Silencing Construct Using Recombinatoral Cloning

Patent Number: 7,846,718

Filed: Jan. 12, 2005

Lead Inventor: Christopher Helliwell, Commonwealth Scientific and Industrial Research Organization

The invention, the patent's abstract states, comprises "methods and vectors and kits … for producing chimeric nucleic acid constructs capable of producing dsRNA for silencing target nucleic acid sequences of interest using recombinational cloning."


Title: Antibody Composition-Producing Cell in Which Enzyme Expression is Inhibited by RNAi

Patent Number: 7,846,725

Filed: April 1, 2008

Lead Inventor: Yutaka Kanda, Kyowa Hakko Kirin

The invention "relates to a cell for the production of an antibody molecule, such as an antibody, useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody, and a fusion protein having the Fc region of the antibody or the like, wherein the expression of GDP-mannose 4,6-dehydrogenase is inhibited by RNA interference," the patent's abstract states.


Title: Double-Stranded RNA and Method of Use for Inhibiting Expression of a Fusion Gene

Patent Number: 7,846,907

Filed: Jan. 22, 2007

Lead Inventor: Olaf Heidenreich, Alnylam Pharmaceuticals

The invention, the patent's abstract states, "relates to the specific inhibition of expression of a fusion gene in mammals using a short double-stranded RNA. The dsRNA is approximately 19 [to] 24 nucleotides in length, and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the … invention are useful for treating diseases caused by chromosomal aberrations, particularly malignant diseases such as lymphoma and leukemia."


Title: RNAi Modulation of TGF-Beta and Therapeutic Uses Thereof

Patent Number: 7,846,908

Filed: March 15, 2007

Lead Inventor: Hans-Peter Vornlocher, Alnylam Pharmaceuticals

The invention "concerns methods of treatment using transforming growth factor-beta modulators," according to the patent's abstract. "More specifically, the invention concerns methods of treating disorders associated with undesirable TGF-beta signaling by administering short interfering RNA which down-regulate the expression of TGF-beta, and agents useful therein."


Title: RNA Interference Induction Element and Use Thereof

Patent Number: 7,847,089

Filed: May 15, 2006 PCT Filed: May 15, 2006

Lead Inventor: Kojiro Ishii, Kurume University

The invention comprises "an RNA interference induction element containing a [pre-defined] nucleotide sequence … and possessing RNA interference induction potential," the patent's abstract states. "Using the RNA interference induction element of the … invention, it is easily possible to knock down a desired target gene, and to produce [an] siRNA for a desired target gene."


Title: Compositions and Methods for siRNA Inhibition of ICAM-1

Patent Number: 7,847,090

Filed: Dec. 5, 2008

Lead Inventor: Samuel Reich, University of Pennsylvania (Opko Health)

"RNA interference using small interfering RNAs which are specific for the ICAM-1 gene inhibits expression of this gene," the patent's abstract states. "Diseases which involve ICAM-1-mediated cell adhesion, such as inflammatory and autoimmune diseases, diabetic retinopathy, and other complications arising from type I diabetes, age-related macular degeneration, and many types of cancer can be treated by administering the small interfering RNAs."


Title: Methods for Mediating Gene Suppression

Application Number: 20100305186

Filed: May 29, 2001 PCT Filed: May 29, 2001

Lead Inventor: Gregory Martin Arndt, Johnson & Johnson Research

The invention, the patent application's abstract states, "is concerned with methods for enhancing gene suppression in cells and, in particular, it is concerned with improved methods for enhancing RNAi-mediated gene silencing by manipulation of factors associated with RNAi. The … invention is also concerned with methods for identifying factors which down-regulate as well as those which up-regulate RNAi. It is also concerned with genetic constructs useful for enhancing or modulating gene silencing and cells harboring such constructs."


Title: Nucleic Acid Capable of Regulating the Proliferation of Cell

Application Number: 20100305188

Filed: Oct. 3, 2008 PCT Filed: Oct. 3, 2008

Lead Inventor: Haruo Nakano, Kyowa Hakko Kirin

The invention, the patent application's abstract states, comprises an "agent for suppressing or promoting cell proliferation, a diagnostic reagent or therapeutic drug for a disease resulting from a cell proliferation abnormality, an agent for inducing apoptosis, an agent for suppressing or promoting the expression of a target gene for a nucleic acid such as a microRNA, and a method of suppressing or promoting cell proliferation."


Title: Nucleic Acid Complex and Nucleic Acid-Delivery Composition

Application Number: 20100305190

Filed: Nov. 6, 2008 PCT Filed: Nov. 6, 2008

Lead Inventor: Hirofumi Takeuchi, Otsuka Pharmaceutical

The invention comprises "a nucleic acid complex with low toxicity and high safety that can persistently maintain a nucleic acid, such as siRNA or the like, in a cell; and a nucleic acid-delivery composition that can efficiently deliver the nucleic acid complex into a cell.

"A nucleic acid complex with low toxicity and high safety that can persistently maintain a nucleic acid in a cell can be obtained by forming a complex using a nucleic acid … and a highly branched cyclic dextrin," it adds. "Moreover, when a carrier comprising a diacylphosphatidylcholine, cholesterol and/or a derivative thereof, and an aliphatic primary amine is used as a nucleic acid-delivery carrier … the safety, the efficiency of intracellular delivery, and the persistence of the nucleic acid in the cell can be further improved."


Title: RNA Interference-Mediated Inhibition of Adenosine A1 Receptor Gene Expression Using Short Interfering RNA

Application Number: 20100305191

Filed: April 5, 2010

Lead Inventor: James McSwiggen, Merck

The invention, the patent application's abstract states, "concerns methods and reagents useful in modulating adenosine A1 receptor gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic-discovery applications. Specifically, the invention relates to small interfering RNA molecules capable of mediating RNA interference against ADORA1 and related receptors."


Title: Compositions and Methods for Short Interfering Nucleic Acid Inhibition of Nav1.8

Application Number: 20100305192

Filed: May 28, 2010

Lead Inventor: Sameer Goregaoker, Schering

"The invention provides short interfering nucleic acids, either single-stranded or double-stranded, that cause RNAi-induced degradation of mRNA from the Nav1.8 sodium channel gene," the patent application's abstract states. It also provides "pharmaceutical compositions comprising such short interfering nucleic acids, recombinant vectors comprising such short interfering nucleic acids, a method for inhibiting translation of an mRNA, a method for inhibiting expression of a polypeptide, a method for blocking the membrane potential in a cell, a method for blocking the sodium current in a cell, and a method for inhibiting chronic pain."


Title: RNAi-Mediated Inhibition of Gremlin for Treatment of IOP-Related Conditions

Application Number: 20100305193

Filed: June 2, 2010

Lead Inventor: Jon Chatterton, Alcon

"RNA interference is provided for inhibition of gremlin in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open-angle glaucoma," the patent application's abstract states.


Title: microRNA Mediator of Cardiomyopathy and Heart Failure

Application Number: 20100305195

Filed: Nov. 9 2007 PCT Filed: Nov. 9, 2007

Inventor: Patrick Umeda, UAB Research Foundation

The patent application, its abstract states, claims a "microRNA, specifically, beta-myosin microRNA, compositions comprising beta-myosin microRNA, and methods of inhibiting or reducing expression of beta-myosin microRNA.

"Also provided are genetically modified cells and animals comprising exogenous beta-myosin microRNA," as well as "methods of screening for agents that modulate beta-myosin microRNA expression … methods of identifying target genes that are regulated by beta-myosin microRNA, and methods of modulating such genes," it adds. "Methods of diagnosing or determining whether a subject is at risk for a cardiovascular disorder are also described."


Title: Cationic Lipids

Application Number: 20100305198

Filed: Oct. 17, 2008 PCT Filed: Oct. 17, 2008

Lead Inventor: Mark Bradley, University of Edinburg

"This invention relates to cationic lipids," the patent application states. "More particularly, the invention relates to biodegradable cationic lipids having a plurality of cationic headgroups and one or more lipophilic tail groups. The lipids are of utility in various applications, and in particular in permitting transfection of molecules, and in particular DNA and RNA, into cells. As such the lipids have specific utility in the field of gene therapy as well as other applications such as delivery of small molecules into cells, detergents, and metal ion complexation for medical or industrial applications."

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.